SKAN Group AG (CH:SKAN)
:SKAN
Want to see CH:SKAN full AI Analyst Report?
Top Page
SKAN Group AG
(SKAN)
Select Model
Select Model
Rating:52Neutral
Price Target:
CHF50.00
▼(-8.26% Downside)
Action:Reiterated
Date:03/26/26
The score is driven primarily by mixed financial performance: strong top-line growth and improved 2025 cash flow are offset by a sharp increase in leverage and weaker 2025 profitability. Technicals are a significant headwind given the clear downtrend and negative momentum indicators. Valuation also weighs on the score due to a high P/E and a modest dividend yield.
Positive Factors
Top-line growth
A 36% revenue rebound in 2025 signals durable demand for SKAN's contamination-control systems and project deliveries. Sustained top-line momentum supports a growing installed base, which increases recurring aftermarket service opportunities and underpins long-term business scale.
Negative Factors
Rising leverage
Debt-to-equity jumping to ~1.15 from near zero materially reduces financial flexibility. Higher leverage increases interest and refinancing risk, constrains ability to fund projects organically, and magnifies downside if margins or cash generation weaken.
Read all positive and negative factors
Positive Factors
Negative Factors
Top-line growth
A 36% revenue rebound in 2025 signals durable demand for SKAN's contamination-control systems and project deliveries. Sustained top-line momentum supports a growing installed base, which increases recurring aftermarket service opportunities and underpins long-term business scale.
Read all positive factors
SKAN Group AG (SKAN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF1.10B
Dividend Yield0.77%
Average Volume (3M)22.50K
Price to Earnings (P/E)67.6
Beta (1Y)0.93
Revenue Growth-7.74%
EPS Growth-58.06%
CountryCH
Employees1,377
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.72
Shares Outstanding22,483,524
10 Day Avg. Volume19,367
30 Day Avg. Volume22,504
Financial Highlights & Ratios
PEG Ratio-1.25
Price to Book (P/B)10.37
Price to Sales (P/S)3.56
P/FCF Ratio56.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF62.50Price Target Upside14.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.36
Revenue Forecast (FY)CHF392.90M
SKAN Group AG Business Overview & Revenue Model
Company Description
SKAN Group AG is a global leader specializing in critical solutions for the pharmaceutical and chemical sectors, offering advanced isolators, cleanroom technologies, and decontamination processes across Asia, Europe, and the Americas. The company ...
How the Company Makes Money
SKAN primarily generates revenue by selling and delivering contamination-control equipment and integrated systems used in sterile pharmaceutical manufacturing (e.g., isolator-based solutions and related aseptic processing/containment systems). Rev...
SKAN Group AG Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
52
Neutral
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 333.33M | 361.30M | 320.02M | 276.95M | 234.26M |
| Gross Profit | 230.31M | 265.88M | 234.08M | 200.50M | 170.11M |
| EBITDA | 36.03M | 59.68M | 50.14M | 40.15M | 32.38M |
| Net Income | 16.27M | 38.80M | 26.31M | 18.99M | 10.62M |
Balance Sheet | |||||
| Total Assets | 481.08M | 384.49M | 373.45M | 388.35M | 331.92M |
| Cash, Cash Equivalents and Short-Term Investments | 94.08M | 61.71M | 85.12M | 135.98M | 131.54M |
| Total Debt | 131.47M | 10.61M | 6.49M | 16.88M | 15.27M |
| Total Liabilities | 353.49M | 181.92M | 197.09M | 222.76M | 157.92M |
| Stockholders Equity | 114.45M | 196.16M | 169.23M | 157.30M | 159.75M |
Cash Flow | |||||
| Free Cash Flow | 21.01M | -7.09M | -26.60M | 32.62M | -32.29M |
| Operating Cash Flow | 64.11M | 46.70M | 8.70M | 61.48M | 10.32M |
| Investing Cash Flow | -130.91M | -69.06M | -17.35M | -76.42M | -11.02M |
| Financing Cash Flow | 108.99M | -9.35M | -15.80M | -4.85M | 67.48M |
SKAN Group AG Technical Analysis
Neutral
54.50
Price Trends
47.91
Positive
49.06
Positive
51.08
Negative
Market Momentum
0.36
Positive
50.69
Neutral
25.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SKAN, the sentiment is Neutral. The current price of 54.5 is above the 20-day moving average (MA) of 50.09, above the 50-day MA of 47.91, and above the 200-day MA of 51.08, indicating a neutral trend. The MACD of 0.36 indicates Positive momentum. The RSI at 50.69 is Neutral, neither overbought nor oversold. The STOCH value of 25.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:SKAN.
SKAN Group AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | CHF4.70B | 16.86 | 27.15% | 0.67% | -2.39% | 154.37% | |
73 Outperform | CHF5.18B | 23.64 | ― | 1.85% | 0.47% | -9.20% | |
71 Outperform | CHF16.91B | 47.14 | ― | 1.02% | 4.05% | -7.94% | |
61 Neutral | CHF1.91B | -17.05 | 4.57% | 2.31% | -5.54% | -264.90% | |
59 Neutral | CHF3.27B | 267.95 | ― | 0.68% | 2.62% | -65.24% | |
52 Neutral | CHF1.10B | 67.63 | ― | 0.77% | -7.74% | -58.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CH:SKAN
SKAN Group AG
49.30
-22.86
-31.68%
CH:SFSN
SFS Group AG
133.00
26.04
24.34%
CH:STMN
Straumann Holding AG
104.65
2.93
2.88%
CH:TECN
Tecan Group AG
151.70
-5.26
-3.35%
CH:YPSN
Ypsomed Holding AG
351.00
-51.37
-12.77%
CH:COTN
COMET Holding AG
427.00
192.78
82.31%
SKAN Group AG Corporate Events
SKAN Shareholders Back All Proposals and Maintain Board Stability
May 7, 2026
SKAN Group AG shareholders approved all proposals at the ordinary general meeting, with nearly 80% of share capital represented, underscoring strong investor support for the company’s governance and payout policy. Investors backed a total di...
SKAN Cushions Vaccine Delays With Services Growth and Digital Expansion
Mar 24, 2026
SKAN Group AG, a leading supplier of aseptic isolator systems and process solutions for pharma and biotech, continued to benefit from robust demand for high-end filling lines, particularly for oncology and biologics, in 2025. The company strengthe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.